1. BreatheSuite
A Medical Device
in your pocket

2. Eric Larson,
PhD Candidate,
Electrical Engineering.
Commercialized past
patent to Belkin.
Co-lead on
BreatheSuite’s patents.
Matt Jasper,
MBA Candidate
Founded 2 IP
licensing businesses.
Handles customer
development.
Mayank Goel,
PhD Candidate,
Computer Science.
Founded home
automation business.
Co-lead on
BreatheSuite’s
patents.
BreatheSuite Team

3. Shwetak Patel
UW Professor in CSE &
EE,
MacArthur Genius Grant
Recipient
Jim Stout, MD
UW Medicine, Spirometry
360 Creator, Primary Care
Physician
Margaret
Rosenfeld, MD
Seattle Children’s
Hospital, Clinical
Pulmonologist
Rachael Tanner &
Kathie Jordan,
Coulter Foundation
David Hammond,
Regulatory Consultant
Greg Free,
GSEC Mentor
Board of Advisors

4. Asthma
COPD
Cystic Fibrosis
Chronic Respiratory Disease

5. World Health Organization
World Asthma Foundation
1 out of every 7 people
have a respiratory
disease

6. Diagnosis: Spirometer
measures volume and
flow of air from the lungs

7. 90% of hospitals in developing
nations do not have spirometers

8. Solution: BreatheSuite

10. From Any Phone

11. Everyone has access

12. BreatheSuite’s Impact
Reduce hospitalizations
Fewer deaths

13. Head To Head Evaluation

14. Head To Head Evaluation
Test results identical
International Conference on Ubiquitous Computing, 2012

15. Head To Head Evaluation
Test results identical
Doctor diagnosis identical
International Conference on Ubiquitous Computing, 2012

16. Current Status

17. Current Status

18. Current Status

19. Current Status

20. Traction: In The News

21. Traction: Key Customers

22. Traction: Key Customers
Global Health Non-
Profits

23. Global Health Non-Profits
Handles: Developing World Healthcare
Needs: mHealth solutions

24. Global Health Market
1 Billion People
6 Billion Phones
World Health Organization

25. Global Health Non-Profits

26. Traction: Key Customers
Global Health Non-
Profits

27. Traction: Key Customers
PharmaceuticalsGlobal Health Non-
Profits

28. Pharmaceuticals: Clinical
Trials
Market: 6000+ respiratory trials
Cost: $1 B per drug
Time: 15 years per drug

29. Go To Market
Pharmaceuticals
DevelopingWorld
Secondary Markets

30. Business Model
PharmaceuticalsGlobal Health Non-
Profits
Setup fee
Per Trial, Per Patient fee
Shared Distribution Channels
Paid Use Model via Buyers

31. Competition
Full Diagnosis
Limited Diagnosis
SoftwareHardware
Spirometers
Peak Flow Meters FEV1 Meters
BreatheSuite

32. Financial Summary
$-
$10
$20
$30
$40
$50
$60
2013
2014
2015
Millions
2013 2014 2015
Revenue $7 $21 $41
Net Income $3 $10 $18
Break Even
in Year 1
M M M
M M M

33. Social Return On Investment

34. Social Return On Investment
Fewer deaths from COPD and asthma
a 10% reduction = 325,000 lives
return of 65M – 1.3B dollars per year
World Health Organization
Burden of Obstructive Lung Disease
World Asthma Foundation

35. Social Return On Investment
Fewer hospitalizations
a 10% reduction > 1M hospital stays
return of 600M – 4B dollars per year
World Health Organization
Burden of Obstructive Lung Disease
World Asthma Foundation

36. Social Return On Investment
Every dollar spent =
conservative: 2.6 dollars of impact
more realistic: 8.6 dollars of impact

37. Offer
Grant Funding:
$800,000
with $100,000
committed
Equity Funding:
$3M-$5M
Grant funding:
commercialization &
regulatory approval
Equity Funding:
Technology scaling &
sales

38. Thank you
Thanks to:
Deb Wolf & the GSEC staff,
Greg Free
GSEC judges and volunteers
BreatheSuite’s board of advisors
The University of Washington
BreatheSuite
A Medical Device
in your pocketwww.breathesuite.com
info@breathesuite.com
@breathesuite

39. BreatheSuite
A Medical Device
in your pocket

40. Appendix: How It Works
Audio
Vocal Tract
Model
Flow rate

41. Appendix: Side By Side
Comparison
Raw Audio: 5.2%
Call In Service:6.4%
ATS Range: 5-7%

42. Appendix: Leading Causes of Death
World Health Organization

43. Appendix: Disability Adjusted Life Years
Global Burden of Disease, 2007

44. Global Health Non-Profits

45. Appendix: Financials: Pharma
Pharma Revenue Projections
Pharma Cost Projections

46. Appendix: Financials: Dev World
Dev World Cost Assumptions
DevWorld Revenues have not been factored into our overall initial
BreatheSuite revenue projections, as the Pharma Revenue is more than
enough to cover both pharma and dev world costs.
However, we are building out a paid use model with developing world
global health partners that includes revenue that will both cover costs,
provide healthy margins, and be affordable to those who need our
technology the most.

47. Appendix: Income Statement & FCF

48. Appendix: Social Impact Summary
Inputs Outputs Outcomes Impacts
$8 M-$39 M
$220M-$2.4 B
$2 B-119 B
$9 B-$365 B
Drugs brought to
market quicker
Increased rates of
smoking cessation
Less hospitalization,
self management of
disease, better health
More trials have
integrated
spirometry results
Spirometry provides
teaching moment for
smokers
Increased number of
people performing
spirometry
Increased number of
people performing
spirometry
Cost of application,
cost of training in
new trials
Doctors, Education &
Ad Campaigns,
Application Services
Time, Access to
phone, Remote Care
Workers, Doctors
Time, Access to
phone, Remote Care
Workers, Doctors
Pharmaceuticals
Developing
Respiratory Drugs
Global Health
Non-Profits
Undiagnosed
COPD patients
Undiagnosed
Asthma Patients
Stakeholders
Less hospitalization,
self management of
disease, better health
Total Impact
$40 B –
$524 B
$8 M-$39 M
$220M-$2.4 B
$20 B-119 B
$20 B-$365 B

49. Appendix: Social Impact Summary
Inputs Outputs Outcomes Impacts
$8 M-$39 M
$220M-$2.4 B
$20 B-119 B
$20 B-$365 B
Drugs brought to
market quicker
Increased rates of
smoking cessation
Less hospitalization,
self management of
disease, better health
More trials have
integrated
spirometry results
Spirometry provides
teaching moment for
smokers
Increased number of
people performing
spirometry
Increased number of
people performing
spirometry
Cost of application,
cost of training in
new trials
Doctors, Education &
Ad Campaigns,
Application Services
Time, Access to
phone, Remote Care
Workers, Doctors
Time, Access to
phone, Remote Care
Workers, Doctors
Pharmaceuticals
Developing
Respiratory Drugs
Global Health
Non-Profits
Undiagnosed
COPD patients
Undiagnosed
Asthma Patients
Stakeholders
Less hospitalization,
self management of
disease, better health
Totals $40 B –
$524 B
$4.1B/yr
$10.6B-
$35B/yr